Randomized Controlled Trial: Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
25 Apr, 2018 | 12:48h | UTCAdjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma – New England Journal of Medicine (free for a limited period)
Commentary: AACR 2018: Adjuvant Pembrolizumab in High-Risk Stage III Melanoma – The ASCO Post (free)